Last reviewed · How we verify

NCT04540237

Serum Cytokine Values in Patients With Granulomatous Mastitis

Completed Last updated 12 January 2021
What this trial tests

trial testing Flow-cytometric analysis in Granulomatous Mastitis in 50 participants. Completed in 1 January 2021.

Timeline
1 September 2020
Primary endpoint
1 January 2021
1 January 2021

Quick facts

Lead sponsorIstanbul Training and Research Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date1 September 2020
Primary completion1 January 2021
Estimated completion1 January 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Training and Research Hospital

Who can join

Adults 18 to 80, female only, with Granulomatous Mastitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying etiologies, including infectious and non-infectious causes. Etiological reasons were examined in various studies, but neither etiology nor definite criteria for diagnosis were found. Our aim in this study is to examine the role of cytokines in differentiating the etiology of granulomatous mastitis and using it as a prognostic marker.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Flow-cytometric analysis

Trials testing the same drug.

Other recruiting trials for Granulomatous Mastitis

Currently open trials in the same condition.

Other Istanbul Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04540237.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing